Market Trends of Lipid Nanoparticles Industry
Therapeutics Segment is Expected to Witness Significant Growth During the Forecast Period
- Lipid nanoparticles (LNPs) are emerging across the pharmaceutical industry as promising vehicles to deliver a variety of therapeutics. These nanoparticles encapsulate and deliver therapeutics to specific locations within the body and release their contents at a desired time. The therapeutic application of lipid nanoparticles in drug delivery, medical imaging, cosmetics, and others is projected to grow in the upcoming years. For instance, according to a study published by the Pharmaceuticals Journal in July 2023, lipid-based nanosystems significantly improved siRNA delivery to tumor cells during breast cancer therapy. Such studies highlight that using lipid nanoparticles for targeted drug delivery enhances treatment outcomes and will likely drive its demand in the coming years.
- In addition, the number of clinical trials devoted to nanoparticles for drug delivery is increasing rapidly due to the continuous development of nanotechnology and advancements in biotechnology and medicine. For instance, per a study published by the International Journal of Molecular Sciences in January 2023, lipid-based nanoparticle drugs accounted for 21% of the US Food and Drug Administration (FDA) approved nanoparticle drugs. Hence, the increasing regulatory approvals for treating a wide range of chronic diseases are expected to contribute to the segment’s growth during the forecast period.
- The recent breakthrough in using lipid nanoparticles for mRNA vaccine delivery for COVID-19 has influenced the interest of several pharmaceutical companies worldwide. For instance, in January 2022, Pfizer Inc. entered an agreement with Acuitas Therapeutics to use the lipid nanoparticle formulation technology of Acuitas for developing mRNA vaccines and therapeutics. Moreover, market players are increasingly focusing on influencing the design and optimization of lipid nanoparticles by incorporating artificial intelligence and machine learning. Such strategic initiatives offer growth opportunities to expand lipid nanoparticle applications in various therapeutic areas, subsequently driving market growth.
- Hence, the therapeutic segment is expected to grow in the coming years due to the treatment benefits lipid nanoparticles offer in drug delivery over conventional methods.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Dominate the Lipid Nanoparticles Market
- North America is expected to dominate the market owing to factors such as developed healthcare infrastructure, growing investment in research and development activities, increasing prevalence of chronic diseases, continuous technological advancement in drug delivery, new product launches, and established players in the region. For instance, according to the National Association of Chronic Disease Directors data published in April 2022, around 60% of the adult American population had at least one chronic disease, among which cancer, diabetes, and cardiovascular disease ranked highest in the United States.
- As per the Canadian Cancer Statistics 2023, about two in five Canadians are expected to develop cancer in their lifetime. Such instances surge the demand for precision medicine to advance the development of lipid nanoparticles for targeted delivery and reduce the burden of diseases, thus influencing market growth in the region. Furthermore, the market is driven by increased government initiatives to support research and development of next-generation medicine. For instance, in April 2023, McGill University received USD 165 million from the government of Canada to support research on next-generation medicines. Hence, these initiatives are expected to fuel the demand for novel therapies to reduce chronic disease burden, subsequently driving the demand for lipid nanoparticles during the forecast period.
- Market players are focusing on strengthening their portfolios by making strategic alliances to expand their geographical presence and growth opportunities in the untapped market, thereby influencing market growth in the region. For instance, in August 2023, Serina Therapeutics Inc., a US-based clinical-stage biotechnology company, signed a merger agreement with AgeX Therapeutics Inc. to advance Serina's lipid nanoparticles and antibody-drug conjugates, which are under clinical study for the treatment of Parkinson's disease and other neurological diseases. Such strategic initiatives by market players to introduce advanced therapeutic measures are expected to contribute to market growth.
- Therefore, the North American region is anticipated to witness growth in the coming years due to the growing focus on personalized medicine and increasing investments by market players in nanotechnology.
Get Analysis on Important Geographic Markets
Download PDF
